Today's Daily Dose brings you news about the pipeline progress of Annovis Bio, new entrants in the COVID-19 drug development space, Livongo Health's upbeat preliminary Q2 revenue, Regeneron's BARDA contract, Novavax stock price touching new high and Mallinckrodt's near-term regulatory catalyst.
Read on…
1. Annovis To Advance ANVS401 Into Parkinson's/ Alzheimer's Study
Annovis Bio Inc. (ANVS) has received clearance from the Central Institutional Review Board to begin a phase II study of its lead compound ANVS401 in early Parkinson's disease and early Alzheimer's disease patients.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.